Curebound today announced it awarded 23 new grants totaling $8.5 million, including a $1 million Cure Prize, to advance promising cancer research.

Cervical cancer is the fourth most common cancer for women in the world, with more than 660,000 new cases and nearly 350,000 ...

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.